Matza Louis S, Howell Timothy A, Chun Bianca, Hetherington Lucinda, White Meghan, Weiss Thomas, Huang Min, Rowen Donna, Tan Tina, Feemster Kristen, Nozad Bayad, Kelly Matthew S, Hoberman Alejandro, Mohanty Salini
Patient-Centered Research, Evidera, 929 N Front St., Wilmington, NC, 28401, USA.
MRL, Merck & Co., Inc., Rahway, NJ, USA.
Qual Life Res. 2025 Mar;34(3):809-821. doi: 10.1007/s11136-024-03840-8. Epub 2025 Jan 3.
Cost-utility analyses examining the value of new vaccines for pneumococcal disease will require health state utilities as inputs. Existing utilities for pneumococcal infections in young children are limited. The purpose of this study was to estimate health state utilities associated with pneumococcal infections in young children.
Six health state vignettes depicting infections due to Streptococcus pneumoniae were drafted based on published literature and clinician interviews. To address methodological challenges in estimating utilities for temporary infections in children 0-5 years of age, several time trade-off approaches were explored in a pilot study (N = 28 participants). In the subsequent utility elicitation study conducted in the UK, health states were valued using the best performing method from the pilot (10-year time horizon, with infections repeated annually) with adult general population respondents imagining a child 2-5 years of age.
A total of 208 participants completed interviews (51.9% female; mean [SD] age = 41.0 [14.9] years). Mean (SD) utilities were 0.902 (0.092) for pneumonia requiring hospitalization, 0.901 (0.087) for bacteremia, 0.894 (0.103) for recurrent acute otitis media (AOM), 0.882 (0.107) for recurrent AOM treated with pressure equalization tubes, 0.878 (0.109) for bacteremic pneumonia, and 0.809 (0.145) for meningitis.
Lower health state utilities were associated with health states that had longer treatment periods, required more invasive treatment, and described more severe infections. Utilities from this study can be used in models examining cost-effectiveness of pneumococcal vaccines. These results have methodological implications for future research estimating utilities associated with temporary pediatric health conditions.
对肺炎球菌疾病新疫苗价值的成本效用分析需要将健康状态效用作为输入。现有的幼儿肺炎球菌感染的效用数据有限。本研究的目的是估计与幼儿肺炎球菌感染相关的健康状态效用。
根据已发表的文献和临床医生访谈,起草了六个描述肺炎链球菌感染的健康状态 vignettes。为了解决估计 0 - 5 岁儿童临时感染效用的方法学挑战,在一项试点研究(N = 28 名参与者)中探索了几种时间权衡方法。在随后于英国进行的效用诱导研究中,使用试点研究中表现最佳的方法(10 年时间范围,感染每年重复)对健康状态进行估值,由成年普通人群受访者想象一个 2 - 5 岁的儿童。
共有 208 名参与者完成了访谈(51.9%为女性;平均[标准差]年龄 = 41.0[14.9]岁)。需要住院治疗的肺炎的平均(标准差)效用为 0.902(0.092),菌血症为 0.901(0.087),复发性急性中耳炎(AOM)为 0.894(0.103),用压力平衡管治疗的复发性 AOM 为 0.882(0.107),菌血症性肺炎为 0.878(0.109),脑膜炎为 0.809(0.145)。
较低的健康状态效用与治疗期较长、需要更侵入性治疗且描述为更严重感染的健康状态相关。本研究的效用可用于检验肺炎球菌疫苗成本效益的模型。这些结果对未来估计与儿童临时健康状况相关效用的研究具有方法学意义。